MarketPulse

ACR-2316

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Acrivon's Dual Drug Combo Shows Promise Against Cancer in Preclinical Trial

Acrivon highlights preclinical data for ACR-368 and ACR-2316 combination therapies at AACR 2026, showing synergies with checkpoint inhibitors and ADCs.
ACRVimmunotherapysynergy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Acrivon's AP3 Platform Shows Promise: ACR-368 Synergies Highlighted at AACR 2026

Acrivon Therapeutics presents preclinical data at AACR 2026 demonstrating strong synergy between its CHK1/2 and WEE1 inhibitors with ADC payloads and immunotherapies.
ACRVendometrial cancerAACR Annual Meeting